BfArM
The article outlines the key points related to reporting serious adverse events in the context of clinical trials.
FDA
The final article dedicated to Diversity Action Plans describes certain specific aspects pertaining to the matter, emphasizing the key considerations.
FDA
The new article is dedicated to enrollment goals, highlighting the aspects related to the rationale behind them and the way they should be measured.
FDA
The new article pays special attention to the content of Diversity Action Plans, emphasizing the aspects related to the relevant goals.
FDA
The new article describes in detail the applicability scope and also outlines specific considerations for certain groups of patients that require special attention in order to ensure they are properly represented among study participants.
#WednesdayWebinar Join us for our upcoming webinar Global Regulatory Changes to Expect in 2025 January 22, 2025 at 10 AM ET
Register Now
